Topiroxostat-FYX-051-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemETopiroxostatCat. No.: HY-14874CAS No.: 577778-58-6Synonyms: FYX-051分式: CHN分量: 248.24作靶点: Xanthine Oxidase作通路: Metabolic Enzyme/Protease储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 23.5 m

2、g/mL (94.67 mM; Need ultrasonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 4.0284 mL 20.1418 mL 40.2836 mL5 mM 0.8057 mL 4.0284 mL 8.0567 mL10 mM 0.4028 mL 2.0142 mL 4.0284 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Topiroxostat(FYX-051)是黄嘌呤氧化还原酶（XOR）抑制剂

3、，IC50为5.3 nM。户使本产品发表的科研献 Expert Opin Ther Targets. 2016;20(3):375-87.1/2 Master of Small Molecules 您边的抑制剂师www.MedChemE Front Pharmacol. 2016 Dec 27;7:518.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Sato T, et al. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazo

4、le, FYX-051 - a xanthine oxidoreductase inhibitor for thetreatment of hyperuricemia corrected. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6225-9.2. Shimo T, et al. Xanthine crystals induced by topiroxostat, a xanthine oxidoreductase inhibitor, in rats, cause transitional cell tumors. ArchToxicol. 2014 Jan 22.3. Matsumoto K, et al. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther. 2011Jan;336(1):95-103.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792; 021-589559